Refractory Overactive Bladder: Sacral NEuromodulation v. BoTulinum Toxin Assessment (ROSETTA).
Phase of Trial: Phase III
Latest Information Update: 14 Mar 2018
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Overactive bladder; Urinary incontinence
- Focus Therapeutic Use
- Acronyms ROSETTA
- 11 Oct 2017 Results of age-related (less than 65 versus greater than 65 years) treatment efficay and safety published in the American Journal of Obstetrics and Gynecology
- 13 Jan 2017 Results published in the Journal of Urology.
- 16 Sep 2016 Results of urinary biomarker analysis presented at the 46th Annual Meeting of the International Continence Society.